Neutral
Nektar Therapeutics reported the results of its Annual Meeting of Stockholders held on June 4, 2026, including the re-election of directors and the ra...
Neutral
Nektar Therapeutics (NKTR) is highlighted as a promising mid-cap healthcare stock, with analysts offering differing perspectives on its future. Wedbus...
Bearish
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NASDAQ:NKTR) regarding potential corporate wrongdoing. The ...